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Epidemiological approach to the atrial fibrillation patients
Atriyal fibrilasyon hastalarına epidemiyolojik yaklaşım
Faruk Ertaş
ÖZET
Atrial fibrilasyon (AF) klinik pratikte en sık görülen arit-
midir. En korkulan komplikasyonu tromboembolik olaylar 
olup  tüm  inmelerin  %  15’inden  tek  başına  sorumludur. 
AF’nin yol açtığı bu önemli komplikasyonu önlemenin en 
etkin yolu antikoagulasyondur. Antikoagülasyonu sağla-
mak için son dönemlerde ortaya çıkan yeni oral antiko-
agülanlarla ilgili çekincelerden dolayı altın standart ajan 
olarak warfarin hala üstünlüğünü sürdürmektedir. Efektif 
antikoagülasyon sağlamada kullanılan farmakolojik ajan-
ların  yanı  sıra  hastanın  demografik  özellikleri  de  (yaş, 
cinsiyet, AF tipi, komorbid durumlar vb.) büyük önem ta-
şımaktadır. AF hastalarının demografik karakteristiği ve 
oral antikoagülan ilaç kullanım profili ile ilgili yapılan çalış-
malar çoğunlukla Batı ve Uzakdoğu kökenli olduğundan 
ülkemizin  gerçek  karakteristiğini  yansıtmamaktadır.  Bu 
çalışmayla ülkemizde AF hastalarında yapılmış olan epi-
demiyolojik çalışmalar analiz edilerek toplumumuz ile ilgili 
verileri literatüre kazandırmayı amaçladık.
Anahtar kelimeler:  Atrial  fibrilasyon,  antikoagülasyon, 
demografik özellikler, epidemiyoloji, kılavuzlar
ABSTRACT
Atrial  Fibrillation  (AF)  is  the  most  common  arrhythmia 
observed in clinical practice. While the thromboembolic 
events  are  the  most  feared  complications,  these  com-
plications alone are responsible for 15% of all strokes. 
Anticoagulation therapy is the most effective way to pre-
vent this significant complication caused by AF. Due to 
the disadvantages related to the recently launched new 
oral anticoagulants, warfarin still maintains its dominance 
as the gold standard agent. Pharmaceutical agents as 
well as demographic characteristics (age, sex, the type 
of AF, co-morbidities etc.) of the patients are crucial to 
provide effective coagulation. Since most of the studies 
on demographic characteristics of AF patients and the 
profile of oral anticoagulant use originate from the West 
and Far East, they do not reflect the real characteristics of 
our country. In this study, by analyzing the epidemiologi-
cal studies conducted among AF patients in our country, 
we aimed to bring literature in data related to our society.
Key words:  Atrial  fibrillation,  anticoagulation,  demo-
graphic characteristics, epidemiology, guidelines
INTRODUCTION
Atrial Fibrillation (AF) is the most common rhythm 
disorders observed in our clinical practice [1]. Its 
prevalence in the general population is 1-2% [2]. 
As an important cause of cardiovascular mortality 
and morbidity with progressively increasing preva-
lence, AF became a serious health issue at the pres-
ent time. Most of the epidemiological studies sug-
gest that AF will be more commonly observed in 
the future. When the increasing and ageing World 
population is considered, the AF frequency increase 
and consequently, related adverse events increase. 
The thromboembolic events are one of the leading 
adverse events. 
In the studies conducted, while AF in associa-
tion with valvular heart disease was demonstrated to 
increase the risk of stroke 17-fold when compared 
to the normal population, nonvalvular AF increased 
the risk of stroke 5-fold [3]. When the results of the 
studies on the effective treatment for the prevention 
of such an important AF-related complication and 
the suggestions of the published guidelines are con-
sidered, effective anticoagulation provided by oral 
coagulant therapy appears to be the most effective 
[4]. Many randomized controlled studies revealed 
that achieved target levels of oral anticoagulation 
reduced the risk of stroke 68%, in unselected pa-
tients with AF [2]. Since the epidemiological stud-F. Ertaş. Epidemiological approach to the atrial fibrillation 333
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ies evaluating the prevalence of AF, demographic 
characteristics of the patients, the antiplatelet/ an-
ticoagulation  medication  use  profile,  the  predic-
tors of oral anticoagulation use have been mostly 
conducted in Western and Far Eastern populations, 
they do not reflect the real characteristics of the pa-
tients with AF in our society [5-8]. In this article, 
we aimed to gather together the prevalence of AF, 
demographic characteristics of the patients, the pro-
file  of  antiplatelet/  anticoagulant  medication  use, 
the physicians’ adherence to the guidelines, and the 
predictors of oral anticoagulant use, in the light of 
the previous epidemiological studies conducted in 
our country and to compare our results with those 
of the studies conducted in Western and Far Eastern 
countries.
Prevalence
The prevalence studies relevant to AF are of North 
American and European origin. According to 
ATRIA (the Anticoagulation and Risk Factors in 
Atrial Fibrillation), Cardiovascular Health Study 
and Framingham records, the overall prevalence of 
AF in a population varies from 0.5% to 1% [1,9-
11]. The prevalence of AF doubles every ten years 
of age and after the age of 80, its prevalence reaches 
10%. In a large epidemiological study recently con-
ducted in Japan including approximately 630 thou-
sand persons over the age of 40, the prevalence of 
AF in population aged over 40 was found as 1.3% in 
males and 0.4% in females [12]. In the same study, 
the prevalence of AF in people over 80 years old 
was found as 4,4% in males and 2,1% in females. In 
another study conducted in Hong Kong, the preva-
lence of AF was found as 1,3% in the age range of 
60-94 [13]. These values show that the prevalence 
of AF in the Far East populations is approximately 
half that of the Western populations. In our coun-
try, data regarding the prevalence of AF come from 
the TEKHARF (Cardiac Diseases and Risk Factors 
in Adults in Turkey) study. In this study including 
three thousand four hundred fifty persons who were 
followed up for ten years, while the overall preva-
lence of AF was reported as 1.25 %, it was reported 
as 0.46% in the age group of 32-59, 2.09% in the 
age group of 60-69 and 2.49% in the age group 70 
and over [14]. Another study conducted on this sub-
ject in our country, is a study of 4721 patients, pre-
sented by Karaçağlar et al. as an experience in a ter-
tiary health care center [1]. In this study assessing 
the prevalence of AF retrospectively regardless of 
age distribution, the prevalence of AF was found as 
9.1% (Table 1).When the data of TEKHARF study 
are particularly considered, the prevalence and in-
cidence of AF in our country show similarity to the 
profile of Far East populations rather than that of 
Western populations.
Types of atrial fibrillation
Although there are different classifications of AF, 
the  most  commonly  used  classifications  in  the 
guidelines published by both AHA (American Heart 
Association) /ACC (American College of Cardiolo-
gy) [16] and ESC (European Society of Cardiology) 
[2] are the classification as valvular and nonvalvu-
lar AF, according the presence or absence of valve 
involvement (mitral stenosis, prosthetic valve) and 
the classification as paroxysmal, persistent or per-
manent AF according to the duration of AF. We 
commonly use these two classifications in clinical 
practice. When evaluating in terms of valve involve-
ment, nonvalvular AF is the most common type of 
AF in World populations [2]. In case of valvular AF, 
with a rate of 22%, our country ranks highest among 
the developed countries records [17,18]. For exam-
ple, the rate of valvular AF was found as 14% in 
Japanese records and 9% in the AFNET study con-
ducted in Germany [5,7]. The prevalence of valvu-
lar AF is definitely related to the high prevalence of 
rheumatic heart disease in our country. When evalu-
ating in terms of the duration of AF, while the most 
common type of AF is the permanent AF in most of 
the studies [1,5,17,19,20], in a study conducted by 
Waldo et al. [6] in American population, the parox-
ysmal AF was reported to be the most common type 
of AF. When the data of our country are considered, 
permanent AF is found to be the most common type 
of AF in single-center studies as well as in the AF-
TER (Atrial Fibrillation in Turkey: Epidemiologic 
Registry) study which reflects the whole Turkish 
society [17] (Table 2).F. Ertaş. Epidemiological approach to the atrial fibrillation 334
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Table 1. Prevalence of atrial fibrillation in several studies
Furberg et al,
 1994
Prevalence of atrial fibrillation in elderly
 subjects (the Cardiovascular 
Health Study).
5201
 subjects
Prevalence of atrial
 fibrillation ≥ 65 age;
Female: 4.8%
Prevalence of atria
l fibrillation ≥ 65 age;
Male: 6.2%
Benjamin et al,
 1994
Independent risk factors for atrial
 fibrillation in a population-based cohort.
The Framingham Heart Study.
4731
 subjects
Prevalence of atrial
 fibrillation between
 55-94 years;
Female: 12.6%
(38 years follow up)
Prevalence of atrial
 fibrillation between
 55-94 years;
Male: 11.2%
(38 years follow up)
Lok et al,
 1996
Prevalence of palpitations, cardiac
 arrhythmias and their associated risk
 factors in ambulant elderly.
1454
 subjects
Prevalence of atrial
 fibrillation between
60-94 years; 1.3 % _
Go et al,
 2001
Prevalence of diagnosed atrial fibrillation
 in adults: national implications for
 rhythm management and stroke
 prevention: the AnTicoagulation and
 Risk Factors in Atrial Fibrillation
 (ATRIA) Study.
17 974
 subjects
Prevalence of atrial
 fibrillation < 80 age:
0.95%
Prevalence of atrial
 fibrillation > 80 age:
9.0%
Uyarel et al,
 2008
Incidence, prevalence, and mortality
 estimates for chronic atrial fibrillation
 in Turkish adults (TEKHARF study)
3450
 subjectes
Prevalence of atrial
 fibrillation general
 population: 1.25% _
Inoue et al,
 2009
Prevalence of atrial fibrillation in
 the general population of Japan:
 an analysis based on periodic
 health examination.
630 138
 subjects
Prevalence of atrial
 fibrillation > 40 age:
Female: 0.4%
Prevalence of atrial
 fibrillation > 40 age:
Male: 1.3%
Karaçağlar 
et al, 2012
The frequency of embolic risk factors
 and adequacy of anti-embolic
 treatment in patients with atrial
 fibrillation: a single tertiary center
 experience, retrospectif study
4721
 subjectes
Prevalence of atrial
 fibrillation general
 population: 9.1% _
rin [24]. In the TEKHARF study the mean age was 
52±13 and in the study conducted by Ertaş et al, 
the mean age was 66±11 [14]. According to the re-
cords of AFTER, the first prospective, multicenter 
study conducted in our country, the mean age of 
AF patients was found as 66.8±12.3 [17,18]. These 
results are consistent with the results of two other 
large epidemiological studies (J-RHYTME study, 
conducted in Japan and the KORAF study examin-
ing the Korean population) [5,8]. The AFNET study 
of 9582 patients conducted in Germany, the aver-
age age was found as 68.4 [7]. This situation may 
be explained by the higher overall average age of 
the Western populations than that of our country. In 
conclusion, our age profile shows similarity to that 
of Far Eastern population. However, in comparison 
with Western populations, our population has AF in 
a younger age (Table 2).
Age
The significant increase in prevalence and throm-
boembolic complications with increasing age is the 
most important common point of the epidemiologi-
cal studies on AF. The increased incidence of AF in 
elderly may be related to several mechanisms. The 
age-related alterations in heart form a significant 
part of the relevant mechanisms [23]. Apart from the 
alterations due to senility, the intensified cardiovas-
cular processes in elderly, resulting in degenerative 
changes in atria and in the cardiac conduction sys-
tem are the other significant factors. A multicenter, 
randomized TAF study published in our country in 
the 2000s which compared the effects of anticoagu-
lants and aspirin on the risk of thromboembolism 
in patients with nonvalvular AF revealed that while 
the mean age of the anticoagulant group was 66.1± 
9.2, it was 63.0±8.7 in the AF group taking aspi-F. Ertaş. Epidemiological approach to the atrial fibrillation 335
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Table 2. Comparison of demographic charecteristics of AF patients
Studies and
 guidelines
Mean age
(years)
Gender  AF type in
 terms of
 valvular
 involvement
AF type in
 terms of
 duration
Valvular AF
 prevalence
(%)
Most common
 comorbidity
Guidelines of
 ACC (American
 College of
 Cardiology) /
AHA (American
 Heart Association) 
/ESC (European
 Society of
 Cardiology)
_ Male
 predominance
Non-valvuler Permanent _ Hypertension
Waldo et al, 2005 NABOR Steering
 Committee.
 Hospitalized patients
 with atrial fibrillation
 and a high
 risk of stroke are not
 being provided with
 adequate
 anticoagulation.
 945 subjects
71.5±13.5 Male
 predominance
Non-valvuler Paroksismal 6 Hypertension
Uyarel et al, 2008 Incidence, prevalence,
 and mortality estimates
 for chronic atrial
 fibrillation in
 Turkish adults
 (TEKHARF study),
 3450 subjects
52±13 Female
 predominance
Non-valvuler Permanent _ Hypertension
Nabauer et al, 2009 The Registry of the
 German Competence
 NETwork on Atrial
 Fibrillation: patient
 characteristics and
 initial management.
 Europace (AFNET
 Study), 9582 subjects
68.4±11.0 Male
 predominance
Non-valvuler Permanent 9 Hypertension
Atarashi et al, 2011 Present status of
 Anticoagulation
 treatment in Japanese
 patients with atrial
 fibrillation: a report
 from the J-RHYTHM
 Registry, 7937 subjects
10.0±68.6 Male
 predominance
Non-valvuler
Permanent 14 Hypertension
Ertas et al, 2012 AFTER (Atrial
 Fibrillation İn Turkey:
 Epidemiologic
 Registry) Study,
 2242 subjects
66.8±12.3 Female
 predominance
Non-valvuler Permanent 22 Hypertension
Shin et al, 2012 KORAF Investigator.
 Trends in Oral
 Anticoagulation
 Therapy Among
 Korean Patients
 With Atrial Fibrillation:
 The KORean Atrial
 Fibrillation Investigation.
5616 subjects
63.6±12.2 Male
 predominance
Non-valvuler Permanent _ Hypertension
Gender
While AF is a more common arrhythmia in the male 
sex, in sex analyses obtained from the population 
studies, study cohorts and cohort studies and sur-
veys, higher thromboembolism rates were detected 
in female sex when compared to those of males. 
This situation made the female sex a parameter of 
CHA2DS2-VASc score which is frequently used 
for the calculation of thromboembolism risks in pa-
tients with AF [2]. When evaluating the data of our 
country in terms of female sex analysis, the inci-
dence of female patients was interestingly found 1.5 F. Ertaş. Epidemiological approach to the atrial fibrillation 336
Dicle Tıp Derg / Dicle Med J    www.diclemedj.org   Cilt / Vol 40, No 2, 332-339
times higher than that of males [17]. This result is 
consistent with the results of the TEKHARF study 
[14]. According to Framingham records examining 
the American society, AF incidence in males was 
1.5 to 2 times higher than females [12]. While the 
Japanese records had a similar incidence in males, 
the rates of female and male patients were found 
close in Korean population [5,8]. When a subgroup 
analysis of AFTER study was performed in order to 
examine the reasons of the difference between the 
data of our country and those of the Western and Far 
Eastern populations, the predominance of valvular 
pathologies in females (358/497; 72% ) appears 
to increase the rate of female patients by 60% in 
the overall cohort [17]. This situation demonstrates 
than the rheumatic heart disease is still a significant 
health problem particularly for the women of our 
country (Table 2).
Co-morbidities 
The presence of pathological conditions associated 
with AF is very important. These pathological con-
ditions significantly contribute to the thromboem-
bolic events of AF patients (a history of cerebrovas-
cular event, hypertension, cardiac failure, diabetes 
mellitus etc.) The incidence of comorbidities asso-
ciated with AF may differ from population to popu-
lation. According to the records of AFTER study 
reflecting our country to a large extent, hyperten-
sion was observed as the most common comorbid-
ity associated with AF (67%). Other associated risk 
factors in patients with AF are heart failure with an 
incidence of 29%, and vascular disease with an inci-
dence of 25%. A story of stroke, transient ischemic 
attack or systemic thromboembolism was present in 
15.3% of the patients [17]. While hypertension was 
similarly the most common comorbidity detected in 
many epidemiological studies conducted in Western 
and Far Eastern populations [5-8,25], a lower rate 
of coronary artery disease was observed in Japa-
nese population when compared with our data [5]. 
On the other hand, a higher rate of coronary artery 
disease was observed in American population when 
compared with our data [6]. While the rate of con-
comitant heart failure in AFTER cohort was simi-
lar to those of the American, Spanish and German 
populations [6,26], it was higher than the Japanese 
population [5]. When the populations were com-
pared to each other in terms of history of stroke, 
while the highest rate was observed in a single cen-
ter study with a rate of 20% [6], a similar rate to 
the results of AFTER (15%) study [17] with a rate 
of 13% was observed in the German population. In 
spite of lower rate of valvular AF, a relatively higher 
rate of ischemic events in these societies may be re-
lated to the higher overall mean age of the patients 
(Table 2).
The assessment of the profile of oral anticoagulant/
antiplatelet use in patients with AF
Although, several medications have been tested, 
and despite the difficulties in its use and its risk of 
bleeding, Warfarin, an oral vitamin K antagonist, 
is commonly used for the pharmacological preven-
tion of stroke in patients with AF. Antithrombotic 
drugs are used for the prevention of stroke in AF 
patients. These drugs are absolutely recommended 
in patients with valvular AF and their use is recom-
mended in nonvalvular AF in line with the scoring 
scheme for the risk of stroke, by AHA/ACC/ESC 
consensus guidelines. Among these new agents, 
even dabigatran etexilate, rivaroxaban and apixaban 
are particularly presented as alternatives to warfa-
rine [27-29] for being the most developed agents 
with maximal evidence and even their properties 
of constant dose no requirement of monitoring and 
predictable  efficacy  are  particularly  emphasized, 
one should remember that it is not clear how to act 
in cases of emergency situations requiring to know 
their  efficiency  in  laboratory  for  making  an  im-
mediate decision, such as the need for emergency 
surgery, the relationships between the intensity of 
complication and the dose, in cases of intoxication 
and how to act in terms of patient compliance and 
failure of the treatment. One should take into ac-
count the cost efficiency of these drugs and the high 
incidence of the valvular AF in our country since 
they are not indicated in valvular AF. Besides, in 
terms of drug safety, one should know that these 
drugs were recently launched for clinical use and 
the phase 4 studies are still in progress and the long 
term monitoring studies are not completed yet.
When all of the disadvantages related the new 
drugs are considered, warfarin seems to maintain 
its position as the gold standard pharmacological 
agent for a long time in oral anticoagulation of AF 
patients. This kind of gold standard and the studies 
conducted on this subject indicate that in Western 
and Far Eastern societies as well as in our society no F. Ertaş. Epidemiological approach to the atrial fibrillation 337
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adequate attention is payed to the subject in clinical 
practice.
In the Euro Heart Survey study [20] the anal-
ysis of 2706 patients with AF revealed that when 
the patients were assessed in terms of the profile 
of oral anticoagulant/ antiplatelet medication use, 
while 57% of all patients were on warfarin treat-
ment alone, 7% were on warfarin+ASA treatment 
and 27% were on ASA treatment alone and 9% of 
the patients were not using any of these treatment 
options. In the J-RYHTHM [5] study of 7937 AF 
patients which was conducted in Japan, while the 
rate of anticoagulant use was 87%, the rate of ASA 
use was found as 22%. In the subgroup analysis 
[30] of the same study, 89% of the 6324 patients 
with nonvalvular AF were on warfarin treatment 
and 23% were on ASA treatment. In these studies 
the effective INR level (2.0-3.0) was achieved only 
in 34% of the patient. According to the data of AF-
TER study, the distribution of the medication use 
of AF patients in our country was as follows: 25% 
of all patients were on warfarin treatment alone, 15 
% were on warfarin+ASA treatment and 42% were 
on ASA treatment alone and 18 % of the patients 
were not receiving any of these treatment options. 
Effective INR levels were detected in 41.3% of 
the patients on oral anticoagulation therapy. When 
the patients were classified according the the risk 
of stroke by using CHA2DS2-VASc scoring, while 
23% of the low risk patients were unnecessarily on 
warfarin therapy, 58% of the high risk patients were 
not receiving anticoagulation therapy [17]. When 
our results were compared with those of the studies 
of Western and Far Eastern origins, while the rates 
of warfarin use were dramatically lower, the effec-
tive INR levels were surprisingly similar to those of 
the aforementioned studies. [5-8] (Table 3). These 
dramatic results obtained from the studies indicate 
that the problem became a global one and they also 
lead in questioning why warfarin is not started when 
indicated.
Table 3. Evaluation of drug profile used in patients with atrial fibrillation
Studies Warfarin
(%)
ASA
(%)
Warfarin+
 ASA (%)
None INR within
 Therapeutic
 range (%)
Nieuwlaat 
et al, 2005
European Heart Survey Investigators.
 Atrial fibrillation management: a prospective
 survey in ESC member countries: the Euro
 Heart Survey on Atrial Fibrillation, 2706
 Subjects (Europian population) 57 27 7 9 34
Waldo et al,
 2005
NABOR Steering Committee. Hospitalized
 patients with atrial fibrillation and a high
 risk of stroke are not being provided with
 adequate anticoagulation. 945 subjects
(American population) 33 25 20 22 _
Atarashi
 et al, 2011
Present status of anticoagulation treatment
 in Japanese patients with atrial fibrillation:
 a report from the J-RHYTHM Registry, 7937
 subjects (Far eastern population) 87 22 18* _ 34
Ertas et al,
 2012
AFTER (Atrial Fibrillation in Turkey:
 Epidemiologic Registry) Study, 2242
 Subjects (Turkish population) 25 42 15 18 41
*Warfarin plus antiplatelet, ASA- acetylsalicylic acid, INR- international normalized ratio
Although  there  are  a  few  specific  studies  of 
Western and Far Eastern origin on this subject, Ba-
zec et al. asserted the following reasons in a meta-
analysis [31] Advanced age, sex, rural settlement, 
language differences, socioeconomic status, falls 
risk, fear of bleeding and disabilities. Based on AF-
TER records, the most common and principal rea-
son in our country was the physician neglect with a 
rate of 69%. The rate of discontinuation of therapy 
by the patients without consulting their physicians F. Ertaş. Epidemiological approach to the atrial fibrillation 338
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was 4%, the rate of the refusal of the treatment was 
4% and the rate of not receiving medication due to 
socioeconomic reasons such as not being able to 
have INR monitored, living alone or living in re-
gions  where  transportation  presented  difficulties, 
was found as 16%. The reasons related to the patient 
was 24% in total. Only 7% of the patients were not 
receiving anticoagulant therapy due to a contraindi-
cation [17].
CONCLUSION
It was determined that the prevalence of AF in the 
overall population in our country was 1.25%, the 
majority of the patients with AF were included in 
nonvalvular and permanent group, the overall aver-
age age of the patients in our country was 65, the 
female sex was dominant over the male population 
hypertension was the most common concomitant 
risk factor, the stroke incidence was 15%, the rate 
of anticoagulant use was 49%, the rate of achieving 
an effective INR level in patients on anticoagulant 
medication was 41.3%, the principal reason of not 
receiving anticoagulant medication was the physi-
cian neglect. On the other hand, it was also demon-
strated that the studies of Western and Far Eastern 
origin did not completely reflect the characteristics 
of our country and warfarin would maintain its posi-
tion as gold standard agent as long as the disadvan-
tages of the newly launched antithrombotic drugs 
continued to exist and the physicians should be 
more careful in their clinical practice particularly in 
the treatment field.
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